cor822

COR822 is a **small molecule arginine gingipain inhibitor** being developed for indications linked to *Porphyromonas gingivalis* pathology. Arginine gingipain is a cysteine protease critical for the survival, replication, and pathogenicity of *P. gingivalis*, a bacterium implicated in periodontal disease and increasingly in neurodegenerative conditions such as Alzheimer’s disease. Inhibiting arginine gingipain may benefit patients by impeding bacterial toxicity and neuroinflammation. COR822 is designed to be brain-penetrant and orally available, with potential use in monotherapy or in combination with lysine gingipain inhibitors. The compound has undergone preclinical development, with IND-enabling studies focusing on manufacturing scaling and toxicology. As of the latest available information, COR822’s highest R&D status is classified as discontinued preclinical, meaning it has not yet entered clinical trials and development may have ceased[3][5][7].

Other names

cor822cor-822cor 822